Following a meeting with the FDA’s Gastrointestinal Drug Advisory Committee Friday, the future of Intercept’s rare liver disease drug Ocaliva is under serious threat. Looking to assess whether Ocaliva ...
The stock is exploding following an announcement that it's on track to be acquired. Alfasigma is poised to buy Intercept at a price of $19 per share. The deal stands a very good chance of being ...
Sept 13 (Reuters) - Independent advisers to the U.S. Food and Drug Administration said on Friday that the available data from Intercept's liver disease drug does not clearly prove its effectiveness or ...
Raw Story, AlterNet and The Intercept sued for copyright infringement over the way the ChatGPT creator trains its technology. By Yiwen Lu Reporting from San Francisco The media outlets Raw Story, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback